Profound pseudohypocalcemia due to gadolinium (Magnevist) contrast in a hemodialysis patient.
We report the first case of profound "pseudohypocalcemia" after the administration of the gadolinium-based contrast media dimeglumine gadopentate (Magnevist; Schering Diagnostics AG, Berlin, Germany) to a long-standing hemodialysis patient. Initial calcium measurements were made by using our routine laboratory colorimetric method based on o-Cresolphthalein (Roche Modular-P; Roche Diagnostics Ltd, Lewes, Sussex, UK). Because the patient was well, with no signs of hypocalcemia, retrospective testing using both another o-Cresolphthalein colorimetric method (Roche Integra 800) and measurement of ionized calcium with an ion-selective electrode were performed, and confirmed laboratory pseudohypocalcemia.
Davenport
Andrew
A
Centre for Nephrology, Department of Clinical Biochemistry, Royal Free Hospital, London, UK. andrew.davenport@royalfree.nhs.uk
Whiting
Stephen
S
D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced*; D008875:Middle Aged; D006435:Renal Dialysis; D012720:Severity of Illness Index
D003287:Contrast Media; D019786:Gadolinium DTPA